Aranorosin circumvents arbekacin-resistance in MRSA by inhibiting the bifunctional enzyme AAC(6')/APH(2″)

J Antibiot (Tokyo). 2012 Oct;65(10):527-9. doi: 10.1038/ja.2012.53. Epub 2012 Jul 4.

Authors

Takuya Suga¹, Takahiro Ishii, Masato Iwatsuki, Tsuyoshi Yamamoto, Kenichi Nonaka, Rokuro Masuma, Hidehito Matsui, Hideaki Hanaki, Satoshi Omura, Kazuro Shiomi

Affiliation

¹ Graduate School of Infection Control Sciences, Kitasato University, Tokyo, Japan.

PMID: 22760297
DOI: 10.1038/ja.2012.53

No abstract available

MeSH terms

Acetyltransferases / antagonists & inhibitors*
Anti-Bacterial Agents / pharmacology*
Dibekacin / analogs & derivatives*
Dibekacin / pharmacology
Drug Resistance, Bacterial / drug effects
Enzyme Inhibitors / pharmacology*
Furans / pharmacology
Humans
Methicillin-Resistant Staphylococcus aureus / drug effects*
Microbial Sensitivity Tests
Molecular Structure
Phosphotransferases (Alcohol Group Acceptor) / antagonists & inhibitors*

Substances

Anti-Bacterial Agents
Enzyme Inhibitors
Furans
aranorosin
Dibekacin
6'-aminoglycoside acetyltransferase-2''-aminoglycoside phosphotransferase
Acetyltransferases
Phosphotransferases (Alcohol Group Acceptor)
arbekacin